The pharmaceutical landscape is currently witnessing a high-stakes confrontation as Shanghai Henlius Biotech maneuvers to intercept Pfizer’s dominance in the next generation of lung cancer therapy. At the heart of this struggle is the development of antibody-drug conjugates (ADCs) targeting PD-L1,
Ivan Kairatov is a leading biopharma expert specializing in the intersection of biotechnology and clinical innovation. With extensive experience in research and development, he has spent his career bridging the gap between laboratory breakthroughs and practical healthcare solutions. In this
Groundbreaking research involving more than twenty thousand oncology patients has finally pulled back the curtain on a quiet crisis where medical treatments are inadvertently failing to account for the fundamental biological differences between men and women. For decades, the medical community
The relentless physical and psychological burden of chronic cholestatic pruritus often defines the daily existence of patients long before a clinical diagnosis is even finalized. For those living with rare liver diseases, the sensation of an internal, unreachable itch is not merely a symptom but a
The current oncology landscape is defined by an urgent need for therapies that can bypass resistance mechanisms in advanced breast cancer while maintaining patient quality of life. Pfizer’s latest clinical data for atirmociclib suggests a significant advancement in achieving this balance through a
The high-stakes landscape of biotechnology often demands that even the most innovative firms execute sudden, clinical-grade course corrections to ensure their long-term survival. Bicycle Therapeutics recently demonstrated this reality by announcing a drastic shift in its corporate strategy, which
